Menopause

The nonhormonal selective neurokinin-3 receptor antagonist fezolinetant was effective and well tolerated in treating moderate to severe vasomotor symptoms associated with menopause, according to study data.

In the February issue of Endocrine Today, experts discussed the health benefits of time-restricted eating.

Menopausal hormone therapy for bothersome vasomotor or other symptoms is safe and appropriate for most women at low atherosclerotic CVD risk, whereas a nuanced approach is needed for intermediate-risk women, researchers reported.

Among postmenopausal women, researchers observed no significant associations between ovarian steroids, adrenal hormones, insulin-like growth factor I, parathormone and vitamin D and handgrip strength, according to study results.

Among midlife women participating in a large longitudinal study, certain phthalate metabolites were associated with higher diabetes incidence over 6 years — but only among white women, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Women in China may be at greater risk for stroke events following menopause, according to a study published in Neurology.

Feb. 3 is Wear Red Day. In support of women’s heart health, Healio and Cardiology Today have curated a list of recent updates in women’s heart health.

Postmenopausal women with hypertension taking estrogen alone or combined with progesterone had a statistically significant increase in systolic blood pressure compare with placebo, according to an analysis of WHI data.

Among postmenopausal women with vulvovaginal atrophy, ospemifene treatment and hormone therapy improved the vaginal microbiome in different ways, according to findings published in Menopause.

Approximately 27% of women in the workplace experience difficulties at work caused by symptomatic menopause, according to a cross-sectional analysis of the Health and Employment After Fifty study.